Registered number
04029624
VERISFIELD (UK) LIMITED
Report and Consolidated Financial Statements
31 December 2022
VERISFIELD (UK) LIMITED
Report and accounts
Contents
Page
Company information 1
Directors' report 2 to 3
Strategic report 4
Independent auditor's report 5 to 7
Consolidated Income statement 8
Consolidated Statement of comprehensive income 9
Consolidated Statement of financial position 10
Company Statement of financial position 11
Consolidated Statement of changes in equity 12
Consolidated Statement of cash flows 13
Notes to the financial statements 14 to 20
VERISFIELD (UK) LIMITED
Company Information
Directors
Mr G Motsios
Mr C Koutsodimos
Mr D Bessios
Auditors
Soteriou Christou Ltd
Chartered Accountants and Statutory Auditors
6A Dickensons Place
London
SE25 5HL
Registered office
6A Dickensons Place
London
SE25 5HL
Registered number
04029624
VERISFIELD (UK) LIMITED
Registered number: 04029624
Directors' Report
The directors present their report and financial statements for the year ended 31 December 2022.
Principal activities
The group's principal activity was that of research, development, registration and marketing of pharmaceutical specialities.
The group's trading activity was generated by the wholly owned subsidiary Verisfield SA registered in Greece. The company's activity during the year was that of holding shares in its subsidiary.
Review of business
The group made a profit in the year of €3,465,761 after tax. The directors believe that the group will continue to operate profitably in the following year as well. All trading was generated by the Greek subsidiary Verisfield SA.
The trading operations of Verisfield SA have been marginally affected by Covid-19 pandemic and the lockdown imposed by the Greeck government, as the company operates in the pharmaceutical sector and the company was allowed to trade throughout the period.
The company had no trading activities during the year.
Future Developments
The group directors are confident that the company will maintain its turnover and profitability. Their aim is to continue to implement the management policies which have been introduced in recent years and which have assisted in successfully overcoming the difficulties and uncertainties in the market place.
The group's priorities is to continue the development of new pharmaceutical products which will ensure that the group operates profitably as well as to continue to increase sales volume to overseas customers where margins are higher than the domestic market.
Employee involvement
The group is committed to offering equal opportunities to both current and prospective employees. The group continues to review and develop best practices and procedures to ensure that all employees are treated fairly in all aspects of employment. It also strives for the diverse enviroment that is supportive of all employees. Individual differences which do not relate to job performance such as gender, marital status, race, colour,ethnic origin,nationality,religion,age or disability are respected.
Research and development
During the year the company spent €2,081,123 on research and development.
Policy and practice on payment of creditors
The group's policy is to settle the terms of payment with suppliers when agreeing the terms of each transaction,to ensure that all suppliers are made aware of the terms of payment and to abide by the terms of payment.
Dividends
During the year the company did not declare any dividends.
Events since the balance sheet date
No events have occurred after the balance sheet date that require disclosure in the accounts.
Directors
The following persons served as directors during the year:
Mr G Motsios
Mr C Koutsodimos
Mr D Bessios
Directors' responsibilities
The directors are responsible for preparing the report and financial statements in accordance with applicable law and regulations.
Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (Financial Reporting Standard 102 and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and group and of the profit or loss of the company and group for that period. In preparing these financial statements, the directors are required to:
select suitable accounting policies and then apply them consistently;
make judgements and estimates that are reasonable and prudent;
state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company and group will continue in business.
The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the group's transactions and disclose with reasonable accuracy at any time the financial position of the group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.
Disclosure of information to auditors
Each person who was a director at the time this report was approved confirms that:
so far as he is aware, there is no relevant audit information of which the group's auditor is unaware; and
he has taken all the steps that he ought to have taken as a director in order to make himself aware of any relevant audit information and to establish that the group's auditor is aware of that information.
This report was approved by the board on 19 October 2023 and signed on its behalf.
Mr C Koutsodimos
Director
VERISFIELD (UK) LIMITED
Strategic Report
The directors presents their strategic report for the company and its subsidiaries for the year to 31 December 2022.
Review and analysis of business during the current year
The group continued its principal activities throughtout the current year.
Following the decision by the UK to leave the European Union, the company had to transfer all pharmaceutical licenses and operations to its subsidiary Verisfield SA which is registered in Greece.
Development and financial performance during the year
As shown in the group's profit and loss account, the group's sales have increased by 1.6 % over the prior year's and the gross profit margin was 49.1% compared to to the previous year's of 49.9% and is in line with the expectations of the group's directors reflecting the current market position. The group's after tax profit was €3,465,761 compared to €3,469,943 in the previous year. The group's profitability was mainly attributed to higher volume of export sales where margins are higher as well as higher volume of sales of profitable products to the domestic market.
The directors in the group monitor the performance of the business and consider the key performance indicator, the gross profit margin, which they have maintained at an acceptable level.
Financial position at the reporting date
The consolidated Financial Position on page 10 shows a net assets position of €7,829,494 compared to a net assets position of €4,363,733 in the previous year. The increase in net assets position is due to increased trading activity and profitability achieved in the year.
Principal risks and uncertainties facing the business
The group regularly reviews the risks faced. Market risk has been identified as a major potential risk to the successful performance of the business. The group directors are aware of these risks and monitor their potential impact on an ongoing basis.
In the normal course of business, the group is subject to a number of risks that are inseparably linked to the operations of its business. The group trades primarily in Greece where risk levels are relatively high due to the economic downturn in recent years and the Greek goverment has pursued a price reduction policy in respect of pharmaceutical products as well as charging a levy which is based on turnover. Even though the group is facing the uncertainty as to whether the Greek goverment will continue its price reduction policy which has an impact on the level of domestic sales and profitability the group will continue its efforts towards development and launch of new profitable products, increase export volumes further where there is no limit on the sales prices that can be charged, continue the sales of licenses for pharmaceutical products for fees or royalties and focus on sales of most profitable products to the Greek market.
Post year end review and Covid-19
The trading operations of Verisfield SA have been marginally affected by the Covid-19 pandemic and the lockdown imposed by the Greeck government as the company deals in pharmaceutical products and was permitted to trade throughout lockdown.
The report was approved by the board on 19 October 2023 and signed on its behalf:
Mr C Koutsodimos
Director
VERISFIELD (UK) LIMITED
Independent auditor's report
to the members of VERISFIELD (UK) LIMITED
Qualified Opinion
We have audited the company and group financial statements of VERISFIELD (UK) LIMITED for the year ended 31 December 2022 which comprise the consolidated Income Statement, the consolidated Statement of Comprehensive Income, the company and consolidated Statement of Financial Position, the consolidated Statement of Changes in Equity, the consolidated Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).
In our opinion, except for the possible effects of the matter described in the basis for qualified opinion section of our report, the financial statements:
give a true and fair view of the state of the company's and group's affairs as at 31 December 2022 and of its profit for the year then ended;
have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice;
have been prepared in accordance with the requirements of the Companies Act 2006.
Basis of qualified opinion
As described in note 16 on page 20, there was no audit evidence available to determine what a reasonable provision might be in respect of the lawsuits for redundancies in the subsidiary accounts. Consequently we have qualified our audit report due to this material uncertainty in determining the extent of any provision required in the accounts.
We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor’s responsibilities for the audit of the financial statements section of our report. We are independent of the company and group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.
Conclusions relating to going concern
In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.
Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.
Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.
Other information
The other information comprises the information included in the report and financial statements, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.
We have nothing to report in this regard.
Opinions on other matters prescribed by the Companies Act 2006
Except for the possible effects of the matter described in the basis for qualified opinion section of our report, in our opinion, based on the work undertaken in the course of the audit:
the information given in the strategic report and the directors’ report for the financial year for which the financial statements are prepared is consistent with the financial statements; and
the strategic report and the directors’ report have been prepared in accordance with applicable legal requirements.
Matters on which we are required to report by exception
In the light of the knowledge and understanding of the company and group and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors’ report.
Arising solely from the limitation on the scope of our work relating to provisions, referred to above:
we have not obtained all the information and explanations that we considred necessary for the purpose of our audit.
We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:
adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
the financial statements are not in agreement with the accounting records and returns; or
certain disclosures of directors’ remuneration specified by law are not made.
Responsibilities of directors
As explained more fully in the directors’ responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible for assessing the company’s and group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or group or to cease operations, or have no realistic alternative but to do so.
Auditor’s responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.
Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:
As part of our planing process:
We considered the audit of the subsidiary and communicated with the component auditors to ensure that we would have appropriate evidence available to us.
We enquired of management the systems and controls the company has in place, the areas of the financial statements that are mostly susceptible to the risk of irregularities and fraud, and whether there was any known, suspected or alleged fraud.
We obtained an understanding of the legal and regulatory frameworks applicable to the company. We determined that the following were most relevant: FRS 102, Companies Act 2006, health and safety, and employment law.
We considered the incentives and opportunities that exist in the company, including the extent of management bias, which present a potential for irregularities and fraud to be perpetuated, and tailored our risk assessment accordingly.
Using our knowledge of the company, together with the discussions held with the company at the planning stage, we formed a conclusion on the risk of misstatement due to irregularities including fraud and tailored our procedures according to this risk assessment.
The key procedures we undertook to detect irregularities including fraud during the course of the audit included:
Identifying and testing journal entries and the overall accounting records, in particular those that were significant and unusual.
Reviewing the financial statement disclosures and determining whether accounting policies have been appropriately applied.
Reviewing and challenging the assumptions and judgements used by management in their significant accounting estimates.
Assessing the extent of compliance, or lack of, with the relevant laws and regulations in particular those that are central to the entities ability to continue in operation.
Testing key revenue lines, for evidence of management bias.
Performing a physical verification of key assets, including stock.
Obtaining third-party confirmation of material balances.
Documenting and verifying all significant related party balances and transactions.
Reviewing documentation such as the company board minutes, correspondance with solicitors, for discussions of irregularities including fraud.
Reviewing the audit of the component auditors to ensure suitable evidence has been obtained.
Testing all material consolidated adjustments.
Owing to the inherent limitations of an audit, there is an unavoidable risk that we may not have detected some material misstatements in the financial statements even though we have properly planned and performed our audit in accordance with auditing standards. The primary responsibility for the prevention and detection of irregularities and fraud rests with the directors.

A further description of our responsibilities for the audit of the accounts is available on the Financial Reporting Council’s website at www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor’s report.
Use of our report
This report is made solely to the company's and group's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's and group's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and group and the company's and group's members as a body, for our audit work, for this report, or for the opinions we have formed.
Panicos Soteriou
(Senior Statutory Auditor) 6A Dickensons Place
for and on behalf of London
Soteriou Christou Ltd SE25 5HL
Accountants and Statutory Auditors
25 October 2023
VERISFIELD (UK) LIMITED
Consolidated Income Statement
for the year ended 31 December 2022
Notes 2022 2021
Turnover 2 17,551,798 17,275,208
Cost of sales (8,939,398) (8,657,879)
Gross profit 8,612,400 8,617,329
Distribution costs (74,673) (55,554)
Administrative expenses (4,619,601) (4,907,900)
Exceptional item - legal claim payment (95,000) -
Other operating income 136,965 13,318
Operating profit 3 3,960,091 3,667,193
Interest receivable 359 3,315
Profit on ordinary activities before taxation 3,960,450 3,670,508
Tax on profit on ordinary activities 6 (494,689) (200,565)
Profit for the financial year 3,465,761 3,469,943
VERISFIELD (UK) LIMITED
Consolidated Statement of comprehensive income
for the year ended 31 December 2022
Notes 2022 2021
restated
Profit for the financial year 3,465,761 3,469,943
Other comprehensive income
Total comprehensive income for the year 3,465,761 3,469,943
VERISFIELD (UK) LIMITED
Consolidated Statement of Financial Position
as at 31 December 2022
Notes 2022 2021
Fixed assets
Intangible assets 7 3,254,461 2,506,397
Tangible assets 8 632,133 527,112
3,886,594 3,033,509
Current assets
Stocks 10 4,891,933 4,214,456
Debtors 11 5,434,756 5,308,777
Cash at bank and in hand 6,092,225 5,445,641
16,418,914 14,968,874
Creditors: amounts falling due within one year 12 (11,822,588) (11,743,361)
Net current assets 4,596,326 3,225,513
Total assets less current liabilities 8,482,920 6,259,022
Creditors: amounts falling due after one year (653,426) (1,895,289)
13
Net assets 7,829,494 4,363,733
Capital and reserves
Called up share capital 14 62,976 62,976
Profit and loss account 15 7,766,518 4,300,757
Total equity 7,829,494 4,363,733
Mr C Koutsodimos Mr G Motsios
Director Director
Approved by the board on 19 October 2023
VERISFIELD (UK) LIMITED
Company Statement of Financial Position
as at 31 December 2022
Notes 2022 2021
Fixed assets
Investments 9 300,000 300,000
300,000 300,000
Current assets
Cash at bank and in hand 5,536 181,676
5,536 181,676
Creditors: amounts falling due within one year 12 (12,196) (171,287)
Net current (liabilities)/assets (6,660) 10,389
Net assets 293,340 310,389
Capital and reserves
Called up share capital 14 62,976 62,976
Profit and loss account 15 230,364 247,413
Total equity 293,340 310,389
The company has taken advantage of the exemption allowed under section 408 of the Companies Act 2006 and has not presented its own statement of comprehensive income in these financial statements. The loss of the company for the year was €17,050 (2021 profit - €152,849).
Mr C Koutsodimos Mr G Motsios
Director Director
Approved by the board on 19 October 2023
VERISFIELD (UK) LIMITED
Consolidated Statement of Changes in Equity
for the year ended 31 December 2022
Share Profit Total
capital and loss
account
At 1 January 2021 62,976 989,814 1,052,790
Profit for the financial year 3,469,943 3,469,943
Dividends (159,000) (159,000)
At 31 December 2021 62,976 4,300,757 4,363,733
At 1 January 2022 62,976 4,300,757 4,363,733
Profit for the financial year 3,465,761 3,465,761
At 31 December 2022 62,976 7,766,518 7,829,494
VERISFIELD (UK) LIMITED
Consolidated Statement of Cash Flows
for the year ended 31 December 2022
Notes 2022 2021
Operating activities
Profit for the financial year 3,465,761 3,469,943
Adjustments for:
Interest receivable (359) (3,315)
Tax on profit on ordinary activities 494,689 200,565
Depreciation 125,500 178,955
Amortisation of intangibles 330,296 245,237
(Increase)/decrease in stocks (677,477) 66,541
Increase in debtors (125,979) (1,645,250)
Decrease in creditors (1,465,760) (832,008)
2,146,671 1,680,668
Interest received 359 3,315
Taxes paid (191,565) (225,747)
Cash generated by operating activities 1,955,465 1,458,236
Investing activities
Payments to acquire intangible fixed assets (1,078,360) (2,258,570)
Payments to acquire tangible fixed assets (230,521) (220,722)
Cash used in investing activities (1,308,881) (2,479,292)
Financing activities
Equity dividends paid - (159,000)
Cash used in financing activities - (159,000)
Net cash generated/(used)
Cash generated by operating activities 1,955,465 1,458,236
Cash used in investing activities (1,308,881) (2,479,292)
Cash used in financing activities - (159,000)
Net cash generated/(used) 646,584 (1,180,056)
Cash and cash equivalents at 1 January 5,445,641 6,625,697
Cash and cash equivalents at 31 December 6,092,225 5,445,641
Cash and cash equivalents comprise:
Cash at bank 6,092,225 5,445,641
VERISFIELD (UK) LIMITED
Notes to the Accounts
for the year ended 31 December 2022
1 Summary of significant accounting policies
Basis of preparation
The financial statements have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland.
The company and its subsidary company Verisfield S.A. form a medium size group which would require consolidation under Companies Act 2006.
Going Concern
The accounts have been prepared on a going concern basis as the directors expect the company to continue its operating existence in the foreseeable future. As explained in more detail in the strategic report, the company's operations have been marginally affected by the Covid-19 pandemic and the lockdown imposed by the Greek goverment, as the company operates in the pharmaceutical sector. In addition the company's priority is to continues to pursue a policy of increasing the export sales volume where high profit margins can be charged, focus on sales to the domestic market of profitable products, sales of licenses of pharmaceutical products for fixed fees or royalties, and development and launch of new profitable products. The directors believe that by focusing on these policies the company has been profitable over the last few years and expect the group will continue to trade profitably for the foreseeable future , and therefore they continue to adopt the going concern basis for accounting in preparing the financial statements.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of pharmaceutical products and licenses and provision of research and development services. Turnover from the sale of the pharmaceutical products and licenses is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of research and development services is recognised by reference to the stage of completion of the service. The stage of completion of a service is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Intangible fixed assets
Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative impairment losses. Amortisation is provided in equal instalments over its estimated economic life of 10 years.
Tangible fixed assets
Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:
Buildings - improvements costs over 25 years
Plant and machinery 10% - 20% straight line
Investments
Investments in subsidiaries, associates and joint ventures are measured at cost less any accumulated impairment losses. Unlisted investments are measured at fair value unless the value cannot be measured reliably, in which case they are measured at cost less any accumulated impairment losses. Changes in fair value are included in the profit and loss account.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost of raw materials is calculated using the weighted average method. The cost of finished and semi-finished products is calculated using the weighted average costs of raw materials and actual for other costs of production.

The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction.

At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Operating lease commitments
Operating lease payments are recognised as an expense on a straight line basis over the lease term.
Research and development
Research and development costs are written off to the profit and loss account in the year the expenditure is incurred.
2 Analysis of turnover 2022 2021
Sale of goods 15,895,170 15,067,758
Services rendered 1,656,628 2,207,450
17,551,798 17,275,208
By geographical market:
Europe 16,042,683 16,223,020
Rest of world 1,509,115 1,052,188
17,551,798 17,275,208
3 Operating profit 2022 2021
This is stated after charging:
Depreciation of owned fixed assets 125,500 178,955
Amortisation of intangibles 330,296 245,237
Operating lease rentals - land and buildings 55,861 62,045
Research and development expenditure 2,081,123 2,439,977
Auditors' remuneration for audit services 9,000 9,000
Auditors' remuneration for other services 3,000 3,000
Carrying amount of stock sold 1,928,848 2,512,223
4 Directors' emoluments 2022 2021
Emoluments 166,679 166,679
5 Staff costs 2022 2021
Wages and salaries 1,446,590 1,488,204
Average number of employees during the year Number Number
Administration 17 14
Development 30 25
Distribution 2 2
Sales and Marketing 2 3
51 44
6 Taxation 2022 2021
Analysis of charge in period
Current tax:
Greek tax on profits of the period 494,689 191,565
Greek witholding tax on dividends paid - 9,000
494,689 200,565
Tax on profit on ordinary activities 494,689 200,565
Factors affecting tax charge for period
The differences between the tax assessed for the period and the standard rate of corporation tax are explained as follows:
2022 2021
Profit on ordinary activities before tax 3,960,450 3,670,508
Standard rate of Greek tax 22% 22%
Profit on ordinary activities multiplied by the standard rate of corporation tax 871,299 807,512
Effects of:
Amounts deductible or adjustible for tax purposes (376,610) (615,947)
Greek witholding tax on dividends - 9,000
Current tax charge for period 494,689 200,565
Factors that may affect future tax charges
There are no such factors.
7 Intangible fixed assets - Group
Trade marks, licenses and other intellectual rights fees
Cost
At 1 January 2022 5,624,656
Additions 1,078,360
At 31 December 2022 6,703,016
Amortisation
At 1 January 2022 3,118,259
Provided during the year 330,296
At 31 December 2022 3,448,555
Carrying amount
At 31 December 2022 3,254,461
At 31 December 2021 2,506,397
8 Tangible fixed assets - Group
Land and buildings Plant and machinery Total
At cost At cost
Cost or valuation
At 1 January 2022 282,305 1,734,425 2,016,730
Additions - 230,521 230,521
At 31 December 2022 282,305 1,964,946 2,247,251
Depreciation
At 1 January 2022 132,348 1,357,270 1,489,618
Charge for the year 11,108 114,392 125,500
At 31 December 2022 143,456 1,471,662 1,615,118
Carrying amount
At 31 December 2022 138,849 493,284 632,133
At 31 December 2021 149,957 377,155 527,112
9 Investments - Company
Investments in
subsidiary
undertakings
Cost
At 1 January 2022 300,000
At 31 December 2022 300,000
The company holds 20% or more of the share capital of the following companies:
Company Shares held
Class %
Verisfield S.A. Ordinary 100
Verisfield S.A. activity is theat of research, development, registration and marketing of pharmaceutical specialities. The company is registered in Greece.
10 Stocks - Group 2022 2021
Raw materials and consumables 3,412,989 2,711,684
Work in progress 5,974 18,503
Finished goods and goods for resale 1,472,970 1,484,269
4,891,933 4,214,456
11 Debtors - Group 2022 2021
Trade debtors 2,740,053 2,890,438
Other debtors 2,694,703 2,418,339
5,434,756 5,308,777
12 Creditors: amounts falling due within one year -Group 2022 2021
Trade creditors 7,046,101 7,277,611
Corporation tax 494,689 191,565
Other taxes and social security costs 125,533 108,844
Other creditors 3,804,134 4,095,198
Accruals and deferred income 352,131 70,143
11,822,588 11,743,361
Creditors: amounts falling due within one year -Company 2022 2021
Other creditors - 159,000
Accruals and deferred income 12,196 12,287
12,196 171,287
13 Creditors: amounts falling due after one year -Group 2022 2021
Other creditors 653,426 1,895,289
14 Share capital Nominal 2022 2022 2021
value Number
Allotted, called up and fully paid:
Ordinary shares £13,500 each 3 62,976 62,976
The company's authorised and issued shared capital is in Pound Sterling.The called up share capital is stated in the balance sheet in Euros following translation using the rate of exchange prevailing on the date of issue.
15 Profit and loss account Group Company
2022 2022
At 1 January 4,300,757 247,413
Profit/(loss) for the financial year 3,465,761 (17,049)
At 31 December 7,766,518 230,364
16 Contingent liability
Lawsuits were filed against the subsidiary Verisfield SA by third parties, claiming damages on the termination of contracts amounting to €167,326. The directors have not made any provision in the accounts in respect of the claims as they are unable to determine the potential liability. The outcome of the claims and the amount payable, if any, will not be known until the cases are heard in the Greek courts.
17 Other Contingent events
During the year the subsidiary Verisfield SA has made an application for a refund based on research and development expenditure incurred in the year. The amount the company is entitled to is uncertain as it will depend on the Greek government allocation and as such no provision for any amounts receivable has been made in the accounts.
18 Related party transactions
At the year end €2,453,282 (2021: €1,822,251) was owed by entities under common control of two of the directors of the group in respect of pharmaceutical licenses fees. The balance is repayable on demand.
19 Controlling party
At the year end there was no single controlling party.
20 Functional currency
The functional currency of the entity is the euro.
21 Legal form of entity and country of incorporation
VERISFIELD (UK) LIMITED is a private company limited by shares and incorporated in England.
22 Principal place of business
The address of the company's registered office is:
6A Dickensons Place
London
SE25 5HL
VERISFIELD (UK) LIMITED 04029624 false 2022-01-01 2022-12-31 2022-12-31 VT Final Accounts April 2022 04029624 2021-01-01 2021-12-31 04029624 bus:AllOrdinaryShares core:RetainedEarningsAccumulatedLosses 2021-01-01 2021-12-31 04029624 countries:RestEuropeOutsideUK 2021-01-01 2021-12-31 04029624 countries:OtherCountriesRegions 2021-01-01 2021-12-31 04029624 core:OwnedAssets 2021-01-01 2021-12-31 04029624 core:LandBuildingsUnderOperatingLeases 2021-01-01 2021-12-31 04029624 bus:OrdinaryShareClass1 2021-01-01 2021-12-31 04029624 core:RetainedEarningsAccumulatedLosses 2021-01-01 2021-12-31 04029624 core:WithinOneYear 2021-12-31 04029624 core:ShareCapital 2021-12-31 04029624 core:RetainedEarningsAccumulatedLosses 2021-12-31 04029624 1 2021-12-31 04029624 2020-12-31 04029624 core:ShareCapital 2020-12-31 04029624 core:RetainedEarningsAccumulatedLosses 2020-12-31 04029624 2022-01-01 2022-12-31 04029624 bus:PrivateLimitedCompanyLtd 2022-01-01 2022-12-31 04029624 bus:Audited 2022-01-01 2022-12-31 04029624 bus:Director1 2022-01-01 2022-12-31 04029624 bus:Director2 2022-01-01 2022-12-31 04029624 bus:Director3 2022-01-01 2022-12-31 04029624 1 2022-01-01 2022-12-31 04029624 core:RetainedEarningsAccumulatedLosses 2022-01-01 2022-12-31 04029624 1 2022-01-01 2022-12-31 04029624 2 2022-01-01 2022-12-31 04029624 countries:RestEuropeOutsideUK 2022-01-01 2022-12-31 04029624 countries:OtherCountriesRegions 2022-01-01 2022-12-31 04029624 core:OwnedAssets 2022-01-01 2022-12-31 04029624 core:LandBuildingsUnderOperatingLeases 2022-01-01 2022-12-31 04029624 core:Goodwill 2022-01-01 2022-12-31 04029624 core:LandBuildings 2022-01-01 2022-12-31 04029624 core:VehiclesPlantMachinery 2022-01-01 2022-12-31 04029624 core:Associate2 2022-01-01 2022-12-31 04029624 core:Associate2 1 2022-01-01 2022-12-31 04029624 1 2022-01-01 2022-12-31 04029624 bus:OrdinaryShareClass1 2022-01-01 2022-12-31 04029624 countries:England 2022-01-01 2022-12-31 04029624 bus:FRS102 2022-01-01 2022-12-31 04029624 bus:FullAccounts 2022-01-01 2022-12-31 04029624 2022-12-31 04029624 core:WithinOneYear 2022-12-31 04029624 core:ShareCapital 2022-12-31 04029624 core:RetainedEarningsAccumulatedLosses 2022-12-31 04029624 core:Goodwill 2022-12-31 04029624 core:LandBuildings 2022-12-31 04029624 core:VehiclesPlantMachinery 2022-12-31 04029624 1 2022-12-31 04029624 bus:OrdinaryShareClass1 2022-12-31 04029624 2021-12-31 04029624 core:Goodwill 2021-12-31 04029624 core:LandBuildings 2021-12-31 04029624 core:VehiclesPlantMachinery 2021-12-31 iso4217:EUR iso4217:EUR xbrli:shares xbrli:pure xbrli:shares